Burn
Drug research and approvals for burn: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 19, 2026, 92 studies of burn are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, and FDA has 1 approved and 6 open orphan designations naming it.
- Recruiting worldwide: 92
- Trials authorized in Canada: 5
- FDA orphan approvals: 1
- EU medicines: 0
- Effect of Targeted Tracheal Kinesio Taping on Cough Efficacy and Decannulation Time in Burned PatientsNCT07932509 · Not applicable · MTI University · starts Nov 10, 2026
- Early Detection and Kinetics of Sepsis-Induced Coagulopathy in Severe Burn PatientsNCT07914205 · Not reported · Center for Traumatology and Major Burns, Ben Arous · starts Aug 1, 2026
- Early Detection and Kinetics of Sepsis-Induced Coagulopathy in Severe Burn PatientsNCT07905807 · Not reported · Selcuk University · starts Oct 24, 2026
- Impact of Inspiratory Muscle Training Post-BurnNCT07867639 · Not applicable · Cairo University · starts Oct 8, 2026
- OCTA Evaluated the Efficacy of Glucocorticoid Retrobulbar Injection in Retinal Photo-injuryNCT07869511 · Not reported · Second Affiliated Hospital, Zhejiang University, School of Medicine · starts Oct 9, 2026
- Red Cell Distribution Width/Albumin Ratio as a Predictive Tool for Mortality of Patients With Burn InjuriesNCT07761845 · Not reported · Ain Shams University · starts Aug 1, 2026
- Hand Function Outcome After the Application of Transfer Energy Capacitive and Resistive on Post-burn Patients Presented…NCT07660328 · Not applicable · Cairo University · starts Aug 9, 2026
- Mitochondrial Energy Metabolism in BurnsNCT07643545 · Not reported · Arkansas Children's Hospital Research Institute · starts Apr 20, 2023
- Scar Remodeling After Burn Injury Using Allogeneic Adipose-derived Stromal CellsNCT07635875 · Phase 1 / Phase 2 · Copenhagen University Hospital, Rigshospitalet · starts Apr 16, 2026
How its trials ended
616 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 138 whose ending is known, 20% met their primary endpoint, 3% missed it and 77% stopped early.
- Completed, result not reported26743%
- Ongoing10918%
- Status unknown10217%
- Stopped: other or unclear6911%
- Met its primary endpoint285%
- Stopped: enrollment or feasibility244%
- Stopped: sponsor or business decision61%
- Missed its primary endpoint41%
- Stopped: funding41%
- Stopped: lack of efficacy3<1%
| Apr 23, 2021 | A randomized, placebo controlled, double-blind, single dose study to evaluate the safety and tolerability of nefopam cream in burn patients with induced dermal…Nefopam (SCX-001) | Governors of The University of Alberta | Closed |
| May 20, 2020 | A phase I, single-blind, randomized study of the safety and efficacy of cellularized integra® using autologous burn-derived stem cells.Integra®-sc | Hamilton Health Sciences Corporation | Pending |
| May 8, 2017 | The effects of metformin on aging biomarkers, morbidity and mortality in burn patients - a prospective randomized controlled trial (RCT)Metformin | Hamilton Health Sciences Corporation | Ongoing |
| Dec 23, 2014 | Sass 2: reconstituted bilamellar autologous skin for permanenet covering of acute phase cutaneous wounds on major burn victimsBilayer autologous reconstructed skin | Centre De Recherche Du Chu De Quebec | Ongoing |
| Oct 7, 2014 | Once daily aminoglycoside pharmacokinetics and optimal dosing in the burn population: a prospective studyTobramycin | Sunnybrook Research Institute | Ongoing |
| Jun 5, 1998 | Sulfamylon solutionFor use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts… | Mylan Laboratories, Inc. | Approved |
| Jun 14, 2021 | Genetically engineered (alpha-1,3-galactosyltransferase…Treatment of severe and extensive, deep partial and full-thickness burn wounds requiring hospitalization, surgical excision, and skin… | XenoTherapeutics, Inc. | Designated |
| Sep 6, 2016 | Bilayer, engineered collagen hydrogel-based skin graft…Treatment of partial deep dermal and full thickness burn wounds | Curtiss AG | Designated |
| Jun 29, 2011 | Fibronectin PeptidePrevention of burn injury progression of acute, deep dermal burns in hospitalized patients. | NeoMatrix Therapeutics, Inc. | Designated |
| May 5, 2004 | IcatibantTreatment of burn patients hospitalized with burn-induced edema | Shire Human Genetic Therapies | Designated |
| Jan 28, 1997 | Dehydroepiandrosterone sulfate sodiumTo accelerate the re-epithelialization of donor sites in those hospitalized burn patients who must undergo autologous skin grafting. | Pharmadigm, Inc. | Designated |
| Mar 6, 1985 | Epidermal growth factor (human)For promotion of cutaneous wound healing in extreme burn treatment protocols. | Ethicon, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA